anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a stable skin cosmetic giving cool feeling to the skin and having excellent usability and safety by mixing water, face lotion, beauty wash or milky lotion to an erythritol-containing non-aqueous skin cosmetic before use. CONSTITUTION:This skin cosmetic is a non-aqueous skin cosmetic containing erythritol, e.g. compounded powder containing erythritol. The powder is mixed with water, face lotion, beauty wash, milky lotion, etc., before use. Cool feeling is given to the skin by the application of the cosmetic. The amount of pentaerythritol to be compounded to the cosmetic is 0.01-100wt.%, preferably 0.1-80wt.%. The skin cosmetic can be used as facial cosmetics (e.g. milky lotion, cream and beauty wash), foundation, make-up cosmetic, body cosmetic, cleaning agent, etc.
BACKGROUND: Moderately differentiated gastric adenocarcinoma (MDGA) has a high risk of metastasis and individual variation, which strongly affects patient prognosis. Using large-scale datasets and machine learning algorithms for prediction can improve individualized treatment. The specific efficacy of several lymph node indicators in predicting distant metastasis (DM) and patient prognosis in MDGA remains obscure.
METHODS: We collected data from MDGA patients from the SEER database from 2010 to 2019. Additionally, we collected data from MDGA patients in China. We used nine machine learning algorithms to predict DM. Subsequently, we used Cox regression analysis to determine the risk factors affecting overall survival (OS) and cancer-specific survival (CSS) in DM patients and constructed nomograms. Furthermore, we used logistic regression and Cox regression analyses to assess the specific impact of six lymph node indicators on DM incidence and patient prognosis.
RESULTS: We collected data from 5,377 MDGA patients from the SEER database and 109 MDGC patients from hospitals. T stage, N stage, tumor size, primary site, number of positive lymph nodes, and chemotherapy were identified as independent risk factors for DM. The random forest prediction model had the best overall predictive performance (AUC = 0.919). T stage, primary site, chemotherapy, and the number of regional lymph nodes were identified as prognostic factors for OS. Moreover, T stage, number of regional lymph nodes, primary site, and chemotherapy were also influential factors for CSS. The nomograms showed good predictive value and stability in predicting the 1-, 3-, and 5-year OS and CSS in DM patients. Additionally, the log odds of a metastatic lymph node and the number of negative lymph nodes may be risk factors for DM, while the regional lymph node ratio and the number of regional lymph nodes are prognostic factors for OS.
CONCLUSION: The random forest prediction model accurately identified high-risk populations, and we established OS and CSS survival prediction models for MDGA patients with DM. Our hospital samples demonstrated different characteristics of lymph node indicators in terms of distant metastasis and prognosis.
The invention discloses a preparation method of an inner ear trans-round window membrane administration slow-released medicine carrier, and relates to inner ear transferring of a series of medicines such as hormone medicines, neurotrophy factor medicines, anti-free-radical medicines, amino glucoside medicines and encephalic antineoplastic medicines. The carrier can coat and transfer the above medicines, can avoid blood brain barrier and blood-labyrinth barrier and can directly cross the round window membrane to enter the inner ear to bring the effect into play by using a tympanum puncture technique. The partial effective medicine concentration of the inner ear is greatly increased, and meanwhile the toxic and side effects caused by a conventional whole body administration mode are greatly alleviated. The invention discloses a technical method for preparing porous albumin micro nanospheres and a slow-released medicine carrier for partial inner ear administration. The preparation method comprises the following steps: dissolving serum albumin in a water solution containing sodium chloride, under the magnetic stirring, adding an absolute ethanol solution, performing hydration treatment, adding glutaraldehyde for fixation, centrifuging, washing with water, and drying, thereby obtaining the porous albumin micro nanosphere blank medicine carrier. A pink composite slow-released micro nanosphere medicine carrier preparation is prepared by commixing rhodamine B as a model medicine with the porous micro nanospheres in a physical adsorption manner.
PURPOSE:To obtain a new compound having action to inhibit a squalene synthetic enzyme and antifungal action and useful in treatment for hypercholesterolemia, coronary arteriosclerotic disease, infection of fungi, etc. CONSTITUTION:A compound of formula I (R1 is H or hydrocarbon; R2 and R3 are H, lower alkyl, phenyl or aromatic heterocycle; X is direct bond or spacer ; Y is carboxyl, OH, amino, phenyl, etc.; the ring A is substitutive), e.g. trans-1-isobutyl-2-oxo-5-(O-tolyl)-l,2,3,5-tetrahydro-4,1-benzoxazepin e-3- aceticacid. The compound of formula I is obtained by using a compound of formula II as a starting substance, passing through 4 steps, introducing into a compound of formula III (R4 is 1-8C alkyl or aralkyl) and treating the compound of formula III with a metal hydride complex compound (e.g. lithium aluminum hydride) in a solvent (e.g. methanol) at -20 to 100 deg.C.
Prepn. of iron choline 1:1:1 citrate comprises reaction of citric acid with choline bicarbonate in equimolar quantities, at ambient temp. and with elimination of carbon dioxide followed by reaction with ferric hydroxide at between 50 and 80 deg.C. - Prod. is recrystallised from water or acetone-methanol. It has use in treatment of iron deficiency anaemias.
Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
PURPOSE:To efficiently produce the enzyme useful, e.g. for therapy of herniated disk by culturing an animal cell having a DNA coding human cathepsin, producing and accumulating this enzyme in the cultured material and collecting it. CONSTITUTION:A human kidney-derived cDNA library lambdagt11 is mixed with distilled water and the resultant mixture is allowed to stand at 95 deg.C for 5min and subsequently quickly cooled in ice water. Two kinds of primers respectively composed of a part of the base sequence of human kidney-derived cathepsin L are added thereto and the PCR reaction is carried out to obtain a cDNA coding human cathepsin by repeating a series of reactions at 94 deg.C for 1min, at 55 deg.C for 2min and at 72 deg.C for 3min 50 times. The resultant cDNA is then treated with a restriction enzyme, subsequently bonded to a vector and introduced into an animal cell such as a mouse myeloma cell to transform it. The obtained transformant is then cultured and this enzyme is produced and accumulated in the cultured material. The accumulated enzyme is collected, thus producing human cathepsin capable of dissolving the nucleus pulposus of a mammal intervertebral disk and useful for therapy of herniated disk.
PURPOSE:To provide a solid or semi-solid oily cosmetic uniform in the coating film therefrom despite adherent feeling, also having spreadability smooth in skin touch. CONSTITUTION:The objective cosmetic containing 30wt.% of an oily ingredient or comprising (A) 100 pts.wt. of the oily ingredient and (B) 0.1-20 (pref. 0.5-10) pts.wt. of fructooligosaccharide powder. The fructooligosaccharide, which is an oligosaccharide with fructose as the chief constituent saccharide, is e.g. a saccharide extracted from Ophiopogonis tuber obtained by drying the roots or their swollen portions of Ophiopogonis tuber or its homologous plants belonging to Liliaceae, or inulin obtained from dahlia, Jerusalem artichoke, or elecampane belonging to Compositae, being pref. 300-10000 in molecular weight. For the fructooligosaccharide powder, it is preferable that the extract be purified through filtration and decolorization, etc., followed by drying.
PROBLEM TO BE SOLVED: To obtain a water-soluble copolymer which can give a clear soln. when dissolved in water by subjecting a water-soluble N-vinyllactam and a hydrophobic comonomer to free-radical copolymn. in an aq. soln. in the presence of an initiator. SOLUTION: A copolymer which can give a clear soln. when dissolved in water is obtd. by subjecting a water-soluble N-vinyllactam represented by the formula (wherein n is 1 or 2) and a hydrophobic comonomer having a water solubility at 20 deg.C of 1-100g/l to free-radical copolymn. in an aq. soln. in the presence of an initiator. The initiator is selected from among an azo initiator, H2 O2 , a hydroperoxide combined with a reducing agent, and a peracid salt and is added in the form of a soln. in water and/or a 1-4C alcohol to the copolymn. mixture.
BACKGROUND: This study aimed to compare the efficacy of robot-assisted partial nephrectomy for completely endophytic renal tumors with the reported outcomes of conventional laparoscopic partial nephrectomy and investigate the transition of renal function after robot-assisted partial nephrectomy.
METHODS: We conducted a prospective, multicenter, single-arm, open-label trial across 17 academic centers in Japan. Patients with endophytic renal tumors classified as cT1, cN0, cM0 were included and underwent robot-assisted partial nephrectomy. We defined two primary outcomes to assess functional and oncological aspects of the procedure, which were represented by the warm ischemic time and positive surgical margin, respectively. Comparisons were made using control values previously reported in laparoscopic partial nephrectomy studies. In the historical control group, the warm ischemia time was 25.2, and the positive surgical margin was 13%.
RESULTS: Our per-protocol analysis included 98 participants. The mean warm ischemic time was 20.3 min (99% confidence interval 18.3-22.3; p < 0.0001 vs. 25.2). None of the 98 participants had a positive surgical margin (99% confidence interval 0-5.3%; p < 0.0001 vs. 13.0%). The renal function ratio of eGFR before and after protocol treatment multiplied by splits was 0.70 (95% confidence interval: 0.66-0.75). Factors such as preoperative eGFR, resected weight, and warm ischemic time influenced the functional loss of the partially nephrectomized kidney after robot-assisted partial nephrectomy.
CONCLUSIONS: Robot-assisted partial nephrectomy for completely endophytic renal tumors offers a shorter warm ischemia time and comparable positive surgical margin rate compared with conventional laparoscopic partial nephrectomy.
BACKGROUND: The lymphatic microsurgical preventive healing approach reduces the risk of lymphedema after axillary lymph node dissection. We identified surgical factors of Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) that influence lymphedema rates focusing on the vein caliber used.
METHODS: A single-institution retrospective cohort study included breast cancer patients undergoing axillary lymph node dissection and LYMPHA (April 2021-November 2022) with a follow-up of at least 1 year. Lymphedema was defined as an increase of ≥10 units in the lymphedema index (measured using bioimpedance spectroscopy) from baseline. The primary outcome was the correlation between the lymphedema index of patients with a vein caliber of ≤2 mm vs > 2 mm.
RESULTS: Forty-eight patients with documented vein caliber were analyzed. The median baseline lymphedema index in patients with a vein caliber ≤2 mm was 2 (SD 3.04) and 2.2 (SD 2.03) for vein caliber >2 mm. (P = .57). After 1-year follow-up, the L-dex was 6.20 (SD 7.48) for vein caliber ≤2 mm and 1.60 (SD 5.85) for vein caliber >2 mm (P = .02). The L-dex difference from baseline was higher for vein caliber ≤2 mm compared to >2 mm (2.9 vs 0.10, P = .02). Larger vein caliber was associated with a lower L-dex at 3 months (P = .04) and a lesser difference from the baseline after 1 year (P = .03). This was maintained on univariate analysis and multivariate analysis controlling for radiation, chemotherapy, and number of lymph nodes excised.
CONCLUSION: Vein caliber >2 mm during LYMPHA axillary lymph node dissection is associated with a lower postoperative lymphedema index. These results can be enhanced by a multi-institutional study to improve standardization of this technique.
Albumens are precipitated from therapeutic serums or other liquids by addition of alkali metal or ammonium salts of acidic metal oxides in admixture with organic acids.  Reagents specified are tungstates, uranates, chromates and vanadates, and acetic acid.  The serum, diluted with water, is preferably treated with a mixture of N/10 sodium vanadate and N/10 acetic acid having a pH value between 3,3 and 5,4.  The albumen-vanadic acid compound is filtered off, and excess of the reagents removed from the filtrate by dialysis through a collodion membrane.ALSO:Therapeutic sera are tested for deviations from normality by the addition of a reagent containing an alkali metal or ammonium salt of an acidic metal oxide in admixture with an organic acid. Reagents specified are tungstates, uranates, chromates, and vanadates, and acetic acid.  Preferably a mixture of N/10 sodium vanadate and N/10 acetic acid having a pH value between 3,3 and 5,4 is employed.  The reagent is ordinarily used for precipitating albumen from the serum, but variations from normality may be determined by treatment with a series of solutions of the reagents containing an increasing vanadium content and decreasing acetic acid content, precipitation of the albumen by a particular solution in this series giving the required indication.ALSO:Therapeutic sera and other liquids containing albumen are treated with alkali metal or ammonium salts of acidic metal oxides in admixture with organic acids, to cause precipitation of the albumen.  Reagents specified are tungstates, uranates, chromates, and vanadates, and acetic acid.  The serum, diluted with water, is preferably treated with a mixture of N/10 sodium vanadate and N/10 acetic acid having a pH value between 3,3 and 5,4.  The albumen-vanadic acid compound is filtered off, and excess of the reagents removed from the filtrate by dialysis through a collodion membrane.  Variations from normality in the serum may be determined, for instance in the diagnosis of cancer, by treatment with a series of solutions of the reagents containing an increasing vanadium content and decreasing acetic acid content.
Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.
A method for producing cannabinoid cooking oil and budder uses a mixture of cannabinoid material and natural oils to produce a consumable spread. The method used a quantity of cannabinoid substance, and a quantity of foaming substance. The foaming substance is a natural oil that can absorb and blend with the cannabinoid substance. The method begins by continuously agitating the cannabinoid substance with the foaming substance until a paste mixture is formed. The method continues by cooling the paste mixture until a solidified mixture is formed. The method concludes by thawing the solidified mixture to yield a tetrahydrocannabinol (THC) infused spreadable paste. Thus, an edible mixture is produced. Some versions of the method feature a flavoring substance that is added to the cannabinoid and foaming substance mixture. Thus, improving flavor.
In 2014, the new intravenous and solid oral formulation of posaconazole were marketed. This offers new treatment possibilities, specifically in patients previously unable to attain adequate exposure to posaconazole solution. To the opinion of the researchers, only limited data are available on the pharmacokinetics (PK) of the new formulations of posaconazole, however, these use strictly selected patients or healthy volunteers, but more importantly, specific aspects related to the PK remain unsolved. Despite the fact that adequate exposure is attained using the new solid oral formulation, it is hypothesized that oral bioavailability of posaconazole may be impacted during mucositis. Whether mucosal barrier injury impacts the absorption of posaconazole or alters presystemic clearance is still unknown. Therefore, it seems prudent to conduct a trial in a group of patients that will experience a severe degree of mucositis to identify changes in absorption of posaconazole and resolving the impact of various stages of mucositis on the PK of posaconazole by linking PK of posaconazole to markers of mucositis (citrulline). This research may also serve as a model for other drugs and allows for direct translations in improving patient care. For this purpose it is needed to determine the PK using both IV and PO dosing of posaconazole.
BACKGROUND: The impact and mechanisms of therapeutic hypothermia (TH) on myocardial ischemia-reperfusion (I/R) injury are still unknown.
METHODS: Sprague-Dawley (SD) rat model and primary cardiomyocytes were applied in our study. TTC staining evaluated myocardial infarction, while H&E staining assessed myocardial injury. ELISA quantified lactate dehydrogenase (LDH), IL-1β, IL-6, and TNF-α. Blood serum concentrations of CK, CK-MB, and cTnT were detected using a biochemical assay. TUNEL assay, flow cytometry and western blot were used to detect cell apoptosis. EdU assay was applied to examine cell proliferation. The expression of DKK3 and β-catenin protein was analyzed using Realtime PCR and Western blot.
RESULTS: TH alleviated myocardial infarction size and injury in rat models of I/R, and reduced serum levels of myocardial injury markers and inflammatory factors in animal and cell models. In addition, TH inhibited the increased apoptosis and β-catenin expression as well as decreased DKK3 expression caused by I/R in I/R cell models, while si-DKK3 reversed the changes brought by TH, and XAV939 inhibited the effects of si-DKK3.
CONCLUSION: TH may reduce myocardial infarction size, myocardial injury, inflammatory response and apoptosis through DKK3/Wnt/β-catenin pathway, thereby alleviating myocardial I/R injury.
Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
Platform identical to the other two used by the experimental groups, configured at 25 Hz, however, without peak-to-peak displacement. The platform starts the engine and emits an operating sound identical to a vibrating platform in operation, but does not generate any mechanical vibration. Participants will be positioned standing, with knees semi-flexed at 30º and must remain on the equipment for 5 minutes each session, three times a week.
Provided are methods of reducing glucose production in a mammal, methods of reducing food intake in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, methods of reducing peripheral blood glucose levels in a mammal, methods of decreasing serum triglyceride levels in a mammal, and methods of decreasing very low density lipoprotein (VLDL) levels in a mammal. The methods comprise administering a compound to the mammal, where administering the compound to the mammal causes an increase in tricarboxylic acid (TCA) cycle flux through acetyl-CoA in the hypothalamus of the mammal. Also provided are methods of increasing glucose production in a mammal and methods of increasing food intake in a mammal. The methods comprise administering a compound to the mammal that causes a decrease in tricarboxylic acid (TCA) cycle flux through acetyl-CoA in the hypothalamus of the mammal and an increase in food intake in the mammal. Additionally provided are methods of decreasing very low density lipoprotein (VLDL) levels in a mammal and decreasing serum triglyceride levels in a mammal. The methods comprise increasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus of the mammal in an amount effective to reduce VLDL or triglyceride levels in the mammal.